Fundamental immune–oncogenicity trade-offs define driver mutation fitness
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Missense driver mutations in cancer are concentrated in a few hotspots 1. Various mechanisms have been proposed to explain this skew, including biased mutational processes 2, phenotypic differences 3–6 and immunoediting of neoantigens 7,8; however, to our knowledge, no existing model weighs the relative contribution of these features to tumour evolution. We propose a unified theoretical ‘free fitness’ framework that parsimoniously integrates multimodal genomic, epigenetic, transcriptomic and proteomic data into a biophysical model of the rate-limiting processes underlying the fitness advantage conferred on cancer cells by driver gene mutations. Focusing on TP53, the most mutated gene in cancer 1, we present an inference of mutant p53 concentration and demonstrate that TP53 hotspot mutations optimally solve an evolutionary trade-off between oncogenic potential and neoantigen immunogenicity. Our model anticipates patient survival in The Cancer Genome Atlas and patients with lung cancer treated with immunotherapy as well as the age of tumour onset in germline carriers of TP53 variants. The predicted differential immunogenicity between hotspot mutations was validated experimentally in patients with cancer and in a unique large dataset of healthy individuals. Our data indicate that immune selective pressure on TP53 mutations has a smaller role in non-cancerous lesions than in tumours, suggesting that targeted immunotherapy may offer an early prophylactic opportunity for the former. Determining the relative contribution of immunogenicity and oncogenic function to the selective advantage of hotspot mutations thus has important implications for both precision immunotherapies and our understanding of tumour evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selforganization of matter and the evolution of biological macromolecules
Eigen, M. (1971) · Die Naturwissenschaften · doi:10.1007/bf00623322 · Cited by 3,788
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Somatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Self-citationBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Mutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Fisher's 'Fundamental Theorem' Made Clear
PRICE, G. R. (1972) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1972.tb00764.x · Cited by 410
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Gene expression analysis identifies global gene dosage sensitivity in cancer
Fehrmann, R. S. N., Karjalainen, J. M., Krajewska, M., Westra, H.-J., Maloney, D., Simeonov, A., Pers, T. H., Hirschhorn, J. N., Jansen, R. C., Schultes, E. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3173 · Cited by 347
Cited by
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Efficacy and safety of immune checkpoint blockade in patients with Li-Fraumeni syndrome
Bottosso, M., Verret, B., Caron, O., Hamzaoui, N., Pasmant, E., Danlos, F.-X., Boudou-Rouquette, P., Srikaran, A., Blons, H., Guarneri, V., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00139 · Cited by 6
Structural changes from wild-type define tumor-rejecting neoantigens
Adams, A. C., Macy, A. M., Borden, E. S., Herrmann, L. M., Brambley, C. A., Sonar, S. A., Ma, T., Li, X., Hughes, A., Roe, D. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013148 · Cited by 4
Metadata
- Authors
- Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., Holm, J. S., Rosenberg, J. E., Shah, S. P., Vázquez-García, I., Weigelt, B., Wu, M., Zamarin, D., Campitelli, L. F., Osborne, E. J., Klinger, M., Robins, H. S., Khincha, P. P., Savage, S. A., Balachandran, V. P., Wolchok, J. D., Hellmann, M. D., Merghoub, T., Levine, A. J., Łuksza, M., & Greenbaum, B. D.
- Venue
- Nature
- Published
- 2022-05-11
- Volume
- 606
- Issue
- 7912
- Pages
- 172-179
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4280534777
- Cited by
- 80
- References
- 11
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fundamental immune–oncogenicity trade-offs define driver mutation fitness. https://app.cochat.ai/papers/10.1038/s41586-022-04696-z
- The paper
- Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., Holm, J. S., Rosenberg, J. E., Shah, S. P., Vázquez-García, I., Weigelt, B., Wu, M., Zamarin, D., Campitelli, L. F., Osborne, E. J., . . . Greenbaum, B. D. (2022). Fundamental immune–oncogenicity trade-offs define driver mutation fitness. Nature. https://doi.org/10.1038/s41586-022-04696-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.